We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.6%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.74B
AUM Growth
+$257M
(+10%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-5.14%
Top 10 Holdings %
Top 10 Hldgs %
33.17%
Holding
165
New
42
Increased
42
Reduced
15
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$60.9M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$57M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$40M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$31.6M |
| 5 |
Globus Medical
GMED
|
+$26.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITMN
INTERMUNE INC
ITMN
|
+$102M |
| 2 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$40.6M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$23.8M |
| 4 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$20.7M |
| 5 |
HCA Healthcare
HCA
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.9% |
| 2 | Financials | 2.94% |
| 3 | Technology | 0.55% |
| 4 | Industrials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUXL
1
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $187M | 6.82% |
6,267,382
| – | – |
|
|
AGN
2
DELISTED
Allergan Inc
AGN
| $87.6M | 3.19% |
491,399
+57,200
| +13% | +$9.5M |
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $80.6M | 2.94% |
6,141,094
+1,241,373
| +25% | +$16.7M |
|
|
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
| $75.2M | 2.74% |
5,258,475
| – | – |
|
|
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
| $70M | 2.55% |
+204,768
| New | +$60.9M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $67.8M | 2.47% |
5,520,566
+4,907,779
| +801% | +$57M |
|
|
ASPX
7
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $64.5M | 2.35% |
2,512,160
+528,122
| +27% | +$11.2M |
|
8
eHealth
EHTH
$47.3M
| $54.6M | 1.99% |
2,264,588
+941,197
| +71% | +$25.7M |
|
|
9
PUT
HCA Healthcare
HCA
$82.3B
| $52.9M | 1.93% |
750,000
| – | – |
|
|
INFI
10
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $52.1M | 1.9% |
3,882,805
+207,967
| +6% | +$2.48M |
|
|
UAM
11
DELISTED
Universal American Corp
UAM
| $48.2M | 1.76% |
5,994,518
+222,781
| +4% | +$1.84M |
|
|
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
| $48.1M | 1.75% |
2,324,917
+974,067
| +72% | +$19.2M |
|
13
DaVita
DVA
$15.2B
| $47M | 1.71% |
642,425
+75,837
| +13% | +$5.55M |
|
|
MNK
14
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $46M | 1.68% |
+510,791
| New | +$40M |
|
|
BLUE
15
DELISTED
bluebird bio
BLUE
| $45.2M | 1.65% |
97,171
+14,160
| +17% | +$6.53M |
|
16
PUT
Tenet Healthcare
THC
$16.8B
| $44.5M | 1.62% |
750,000
| – | – |
|
17
AbbVie
ABBV
$450B
| $44.3M | 1.61% |
766,400
+225,000
| +42% | +$12.5M |
|
|
ARRY
18
DELISTED
Array Biopharma Inc
ARRY
| $43.6M | 1.59% |
12,205,673
| – | – |
|
19
CALL
Humana
HUM
$48B
| $36.5M | 1.33% |
280,000
| – | – |
|
|
AGN
20
CALL
DELISTED
Allergan Inc
AGN
| $35.6M | 1.3% |
200,000
+100,000
| +100% | +$16.6M |
|
21
PUT
Cigna
CI
$74.5B
| $34M | 1.24% |
375,000
| – | – |
|
|
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $30.9M | 1.13% |
2,428,569
| – | – |
|
|
AET
23
PUT
DELISTED
Aetna Inc
AET
| $30.4M | 1.11% |
375,000
| – | – |
|
|
DYAX
24
DELISTED
DYAX CORPORATION
DYAX
| $29.9M | 1.09% |
2,954,684
-762,329
| -21% | -$7.38M |
|
|
KITE
25
DELISTED
Kite Pharma, Inc.
KITE
| $28.8M | 1.05% |
+1,011,998
| New | +$25M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2014 Portfolio in Review
As of Q3 2014, Deerfield Management held 165 positions worth $2.74B, up 10% from $2.49B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Deerfield Management withdrew a net $141M in Q3 2014, closing 34 positions and reducing 15 holdings. Its most notable exit was INTERMUNE INC, an estimated $102M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Adverum Biotechnologies worth $70M.
- Deerfield Management's largest Q3 2014 buy was Adverum Biotechnologies: 204,768 shares worth $70M.
- Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014, an estimated $57M increase.
- Deerfield Management's biggest Q3 2014 reduction was Keryx Biopharmaceuticals Inc, cutting an estimated $40.6M.
- Deerfield Management fully exited INTERMUNE INC in Q3 2014, selling an estimated $102M.
- Deerfield Management's ten largest holdings make up 33% of its $2.74B portfolio in Q3 2014.
- Deerfield Management opened 42 new positions and closed 34 in Q3 2014.
- Deerfield Management's portfolio value rose 10% quarter-over-quarter to $2.74B.
Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.